Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ
19.65
-0.65 (-3.18%)
Closed
Oct 7, 2026
Day's Range
19.5320.53
52 wk Range
9.5621.18
Financial Statements - AMRX - Amneal Pharmaceuticals, Inc.
Revenue
3.01B▲ 8.0%
Net Income
127.93M▲ 273.2%Net Margin 4.2%
EBITDA
606.64M▲ 1.9%
Free Cash Flow
225.63M▲ 2.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 3.01B | 2.79B | 2.39B | 2.21B | 2.09B | 1.99B |
| Cost of Goods | 1.90B | 1.77B | 1.57B | 1.42B | 1.32B | 1.36B |
| Gross Profit | 1.11B | 1.02B | 820.56M | 784.70M | 768.97M | 628.39M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 397.91M | 347.44M | 224.25M | 188.92M | 193.90M | 111.08M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 13.75M | -143.86M | -13.08M | -278.38M | -26.21M | -863K |
| Pre Tax Income | 139.20M | -55.01M | -40.27M | -248.12M | 31.36M | -35.78M |
| Income Tax | 11.27M | 18.86M | 8.45M | 6.66M | 11.19M | -104.35M |
| Net Income | 127.93M | -73.87M | -48.72M | -254.78M | 20.17M | 68.57M |
| EPS Basic | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 | 0.62 |
| EPS Diluted | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 | 0.61 |
| Basic Shares Outstanding | 313.36M | 308.97M | 176.13M | 150.94M | 148.92M | 147.44M |
| Diluted Shares Outstanding | 313.36M | 308.97M | 176.13M | 150.94M | 148.92M | 147.44M |
| Ebit | 380.30M | 203.58M | 170.35M | -89.75M | 167.69M | 110.21M |
| Ebitda | 606.64M | 595.41M | 417.96M | 446.63M | 442.64M | 349.05M |
| Net Income Continuous Operations | 127.93M | -73.87M | -48.72M | -254.78M | 20.17M | 68.57M |
| Minority Interests | -55.87M | -43.01M | -35.27M | 124.80M | -9.54M | 22.48M |
| Preferred Stock Dividends | - | - | - | - | - | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
